Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer
Launched by SANOFI · Feb 24, 2009
Trial Information
Current as of May 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histologically proven adenocarcinoma of the colon or the rectum
- • Metastatic disease not amenable to potentially curative treatment
- Exclusion Criteria:
- • Prior therapy for metastatic cancer of the colon or the rectum
- • Prior treatment with angiogenesis inhibitors
- • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
About Sanofi
Sanofi is a global healthcare leader dedicated to empowering life through innovation in pharmaceuticals and vaccines. With a strong commitment to research and development, Sanofi focuses on addressing complex health challenges across various therapeutic areas, including diabetes, oncology, immunology, and rare diseases. The company leverages advanced science and technology to develop transformative therapies that improve patient outcomes. Through collaborative partnerships and a patient-centric approach, Sanofi strives to enhance global health and deliver sustainable solutions that meet the evolving needs of healthcare systems and communities worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Manchester, , United Kingdom
Douglas, , Australia
Hunter Region Mail Centre, , Australia
Hunter Region Mail Centre, , Australia
Berlin, , Germany
Dresden, , Germany
Hannover, , Germany
Homberg, , Germany
Mannheim, , Germany
Münster, , Germany
Recklinghausen, , Germany
Bari, , Italy
Firenze, , Italy
Milano, , Italy
Taormina, , Italy
Torino, , Italy
Busan, , Korea, Republic Of
Cheongju, , Korea, Republic Of
Daegu, , Korea, Republic Of
Daejeon, , Korea, Republic Of
Goyang Si, Gyeonggi Do, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Ulsan, , Korea, Republic Of
Pyatigorsk, , Russian Federation
Saint Petersburg, , Russian Federation
Sochi, , Russian Federation
Barcelona, , Spain
Madrid, , Spain
Madrid, , Spain
Sabadell, , Spain
Santiago De Compostela, , Spain
Valencia, , Spain
Leeds, , United Kingdom
Leicester, , United Kingdom
Slough, , United Kingdom
Southampton, , United Kingdom
Patients applied
Trial Officials
John Zalcberg, MD
Principal Investigator
Peter Mc Callum Cancer Centre, Melbourne, Australia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials